Skip to main content
Bavarian Nordic logo

Bavarian Nordic — Investor Relations & Filings

Ticker · BAVA ISIN · DK0015998017 LEI · 2138006JCDVYIN6INP51 CO Manufacturing
Open in API
Filings indexed 2,297 across all filing types
Latest filing 2024-05-31 Regulatory Filings
Country DK Denmark
Listing CO BAVA

About Bavarian Nordic

https://www.bavarian-nordic.com/

Bavarian Nordic is a fully integrated biotechnology company specializing in the research, development, manufacturing, and commercialization of life-saving vaccines. The company's portfolio targets infectious diseases, including vaccines for Mpox, rabies, and typhoid. It is a leading global provider of travel vaccines and serves as a key partner for governments and international organizations in addressing public health preparedness needs.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a press release dated May 31, 2024, announcing that Bavarian Nordic has submitted a supplemental Biologics License Application (sBLA) to the U.S. FDA for a freeze-dried formulation of its vaccine. This announcement discusses regulatory submissions, clinical data, government contracts (BARDA), and financial guidance implications. It is not a full Annual Report (10-K), an Interim Report (IR), or a formal Audit Report (AR). It is a specific corporate update regarding regulatory progress and potential future contracts. Since it details a significant regulatory submission and business development event, it fits best under the general category of Regulatory Filings (RNS) as it is a broad announcement of a material event, although it is highly specific. It is not a management report (MDA) which usually accompanies earnings, nor is it a specific financing event (CAP). Given the nature of the announcement (submission to FDA), RNS is the most appropriate general regulatory filing category when a more specific category like 'LTR' (Legal Proceedings) or 'TAR' (M&A) does not apply. It is a direct announcement of a regulatory action.
2024-05-31 English
Regulatory Filings 2024
Regulatory Filings Classification · 100% confidence The document is a press release from Bavarian Nordic, dated May 31, 2024, written in Danish. The core content announces the submission of a supplementary application to the FDA for approval of a freeze-dried version of their JYNNEOS vaccine. This type of announcement, detailing regulatory progress, clinical trial data summaries, management commentary, and financial outlook related to a specific corporate event (regulatory submission), strongly aligns with an Earnings Release (ER) or a general corporate announcement. Since it is not a full financial report (10-K or IR), nor a transcript (CT), nor a specific management compensation report (DEF 14A), it fits best as an Earnings Release (ER) which often includes significant operational and regulatory updates, or potentially a Regulatory Filing (RNS) if it were purely a notification. Given the depth of operational and financial context (mentioning existing contracts, production timelines, and unchanged 2024 guidance), ER is a strong candidate. However, the document structure and content are typical of a general corporate news release announcing a major regulatory milestone. Since 'ER' is defined as the *initial announcement of periodical financial results (key highlights only)*, and this is a specific regulatory update, the most appropriate general category for a significant, non-standard corporate announcement that doesn't fit elsewhere is Regulatory Filings (RNS), as it is a formal communication to the market about a regulatory action. Given the context of a major regulatory submission, RNS is the safest classification, although ER is plausible if this was released alongside quarterly results, which is not explicitly stated. I will classify it as RNS as it is a formal regulatory update announcement that doesn't fit the specific financial report codes.
2024-05-31 Danish
Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Smallpox and Mpox Vaccine
Regulatory Filings Classification · 95% confidence The document is a corporate announcement (Selskabsmeddelelse) from Bavarian Nordic regarding the submission of a supplemental application to the FDA for a freeze-dried vaccine. It details the regulatory progress, clinical data, and the impact on existing government contracts. It does not fit into specific financial reporting categories like 10-K or ER, nor is it a simple report publication announcement (RPA) as it provides substantive operational news. Therefore, it is classified as a general regulatory filing/announcement.
2024-05-31 Danish
Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Smallpox and Mpox Vaccine
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' from Bavarian Nordic regarding the submission of a supplemental Biologics License Application (sBLA) to the U.S. FDA. It details the regulatory progress of a specific product (JYNNEOS) and mentions existing government contracts. Since it is a general regulatory announcement regarding company operations and product development that does not fit into specific categories like financial reports, earnings releases, or board changes, it is best classified as a general regulatory filing.
2024-05-31 English
Share Issue/Capital Change 2024
Share Issue/Capital Change Classification · 99% confidence The document explicitly details a 'Capital Increase' resulting from the exercise of employee warrants, leading to the issuance of 18,702 new shares and an increase in the total nominal share capital. This action directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition of 'Share Issue/Capital Change' (Code: SHA). Although it involves financing, the core event is the issuance of new shares, making SHA more specific than CAP (Capital/Financing Update). The document is a formal announcement of the event, not just a notice that a report is attached.
2024-05-22 English
Share Issue/Capital Change 2024
Share Issue/Capital Change Classification · 99% confidence The document text is a short announcement (3150 characters) in Danish titled 'Kapitalforhøjelse i Bavarian Nordic A/S som følge af medarbejderes udnyttelse af tegningsoptioner' (Capital increase in Bavarian Nordic A/S due to employees exercising warrants). It details the issuance of new shares, the resulting capital increase, and the total number of shares outstanding. This clearly relates to changes in the company's capital structure and financing activities. This aligns directly with the definition for 'Capital/Financing Update' (CAP). Although it involves share issuance, the primary focus is the capital structure change resulting from employee option exercise, which fits CAP better than SHA (Share Issue/Capital Change) which is broader, or POS (Transaction in Own Shares) which usually implies buybacks/treasury stock transactions. Given the content, CAP is the most precise fit.
2024-05-22 Danish

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.